[Understanding and comments of the series of uncertain viewpoints on the diagnosis and treatment of AAOMS medication-related osteonecrosis of the jaw].

This article focuses on the series of viewpoints on the prevention and treatment of medication-related osteonecrosis of the jaw issued by the American Association of Oral and Maxillofacial Surgery (AAOMS), and puts forward several uncertain issues from a clinical perspective. The points of doubt in diagnosis include the definition of drug categories and the threshold of bone exposure duration, as well as the significance of imaging features of bone lesions for diagnostic and treatment decisions. The concerns in terms of prevention include drug risks and disease incidence, tooth extraction and drug holiday, intervention measures promoting bone wound healing and their effectiveness. In terms of treatment, with integration of the author's practical experience, the discussion points focused on the dominant principles of non-surgical treatment, the identification and confirmation of the surgical bone incision boundary, the application of buccal fat pads, chin flaps and submandibular gland transposition, as well as the applicable conditions for permanent repair of fibular transplantation, temporary repair of reconstruction plate bridging, compromise mandibular resection and maxillary sinus opening, etc. The article suggests seeking evidence-based research on the above issues.